Go Pro
→ The dollar reset no one told you about (From Porter & Company) (Ad)tc pixel Free NMTC Stock Alerts

NeuroOne Medical Technologies (NMTC) Competitors

NeuroOne Medical Technologies logo
$1.77 -0.21 (-10.61%)
As of 08/28/2026 04:00 PM Eastern
Compare

NMTC vs. NRXS, NNOX, NYXH, HSAQ, and DXR

Should you buy NeuroOne Medical Technologies stock or one of its competitors? NeuroOne Medical Technologies's main competitors and comparable companies include NeurAxis (NRXS), Nano-X Imaging (NNOX), Nyxoah (NYXH), Health Sciences Acquisitions Co. 2 (HSAQ), and Daxor (DXR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does NeuroOne Medical Technologies compare to NeurAxis?

NeurAxis (NASDAQ:NRXS) and NeuroOne Medical Technologies (NASDAQ:NMTC) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, dividends, media sentiment, valuation, profitability, institutional ownership, risk and analyst recommendations.

NeurAxis presently has a consensus price target of $13.00, suggesting a potential upside of 116.67%. NeuroOne Medical Technologies has a consensus price target of $7.33, suggesting a potential upside of 314.31%. Given NeuroOne Medical Technologies' higher probable upside, analysts clearly believe NeuroOne Medical Technologies is more favorable than NeurAxis.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
NeurAxis
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
NeuroOne Medical Technologies
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.40

NeuroOne Medical Technologies has a net margin of -71.50% compared to NeurAxis' net margin of -492.76%. NeurAxis' return on equity of 0.00% beat NeuroOne Medical Technologies' return on equity.

Company Net Margins Return on Equity Return on Assets
NeurAxis-492.76% N/A -641.25%
NeuroOne Medical Technologies -71.50%-128.12%-86.34%

NeuroOne Medical Technologies has higher revenue and earnings than NeurAxis. NeurAxis is trading at a lower price-to-earnings ratio than NeuroOne Medical Technologies, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NeurAxis$5.32M14.17-$14.63M-$0.78N/A
NeuroOne Medical Technologies$9.47M1.70-$3.61M-$0.95N/A

In the previous week, NeuroOne Medical Technologies had 5 more articles in the media than NeurAxis. MarketBeat recorded 5 mentions for NeuroOne Medical Technologies and 0 mentions for NeurAxis. NeuroOne Medical Technologies' average media sentiment score of 0.41 beat NeurAxis' score of 0.00 indicating that NeuroOne Medical Technologies is being referred to more favorably in the news media.

Company Overall Sentiment
NeurAxis Neutral
NeuroOne Medical Technologies Neutral

NeurAxis has a beta of 1.49, indicating that its stock price is 49% more volatile than the broader market. Comparatively, NeuroOne Medical Technologies has a beta of 0.61, indicating that its stock price is 39% less volatile than the broader market.

11.8% of NeurAxis shares are owned by institutional investors. Comparatively, 16.1% of NeuroOne Medical Technologies shares are owned by institutional investors. 21.1% of NeurAxis shares are owned by company insiders. Comparatively, 11.8% of NeuroOne Medical Technologies shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

NeuroOne Medical Technologies beats NeurAxis on 10 of the 16 factors compared between the two stocks.

How does NeuroOne Medical Technologies compare to Nano-X Imaging?

NeuroOne Medical Technologies (NASDAQ:NMTC) and Nano-X Imaging (NASDAQ:NNOX) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, earnings, profitability, dividends, analyst recommendations, valuation, media sentiment and institutional ownership.

In the previous week, Nano-X Imaging had 1 more articles in the media than NeuroOne Medical Technologies. MarketBeat recorded 6 mentions for Nano-X Imaging and 5 mentions for NeuroOne Medical Technologies. Nano-X Imaging's average media sentiment score of 0.48 beat NeuroOne Medical Technologies' score of 0.41 indicating that Nano-X Imaging is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
NeuroOne Medical Technologies
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Nano-X Imaging
1 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

NeuroOne Medical Technologies currently has a consensus price target of $7.33, indicating a potential upside of 314.31%. Nano-X Imaging has a consensus price target of $4.33, indicating a potential upside of 422.34%. Given Nano-X Imaging's stronger consensus rating and higher possible upside, analysts clearly believe Nano-X Imaging is more favorable than NeuroOne Medical Technologies.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
NeuroOne Medical Technologies
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.40
Nano-X Imaging
1 Sell rating(s)
2 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
2.50

16.1% of NeuroOne Medical Technologies shares are owned by institutional investors. Comparatively, 21.5% of Nano-X Imaging shares are owned by institutional investors. 11.8% of NeuroOne Medical Technologies shares are owned by company insiders. Comparatively, 7.7% of Nano-X Imaging shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

NeuroOne Medical Technologies has higher earnings, but lower revenue than Nano-X Imaging. NeuroOne Medical Technologies is trading at a lower price-to-earnings ratio than Nano-X Imaging, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NeuroOne Medical Technologies$9.47M1.70-$3.61M-$0.95N/A
Nano-X Imaging$14.52M4.49-$75.02M-$1.58N/A

NeuroOne Medical Technologies has a beta of 0.61, meaning that its stock price is 39% less volatile than the broader market. Comparatively, Nano-X Imaging has a beta of 1.26, meaning that its stock price is 26% more volatile than the broader market.

NeuroOne Medical Technologies has a net margin of -71.50% compared to Nano-X Imaging's net margin of -716.44%. Nano-X Imaging's return on equity of -70.96% beat NeuroOne Medical Technologies' return on equity.

Company Net Margins Return on Equity Return on Assets
NeuroOne Medical Technologies-71.50% -128.12% -86.34%
Nano-X Imaging -716.44%-70.96%-62.26%

Summary

Nano-X Imaging beats NeuroOne Medical Technologies on 12 of the 17 factors compared between the two stocks.

How does NeuroOne Medical Technologies compare to Nyxoah?

Nyxoah (NASDAQ:NYXH) and NeuroOne Medical Technologies (NASDAQ:NMTC) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, dividends, risk, institutional ownership, profitability and valuation.

In the previous week, NeuroOne Medical Technologies had 3 more articles in the media than Nyxoah. MarketBeat recorded 5 mentions for NeuroOne Medical Technologies and 2 mentions for Nyxoah. Nyxoah's average media sentiment score of 1.28 beat NeuroOne Medical Technologies' score of 0.41 indicating that Nyxoah is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Nyxoah
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
NeuroOne Medical Technologies
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Nyxoah presently has a consensus price target of $4.26, indicating a potential upside of 166.38%. NeuroOne Medical Technologies has a consensus price target of $7.33, indicating a potential upside of 314.31%. Given NeuroOne Medical Technologies' stronger consensus rating and higher probable upside, analysts plainly believe NeuroOne Medical Technologies is more favorable than Nyxoah.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Nyxoah
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.25
NeuroOne Medical Technologies
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.40

NeuroOne Medical Technologies has lower revenue, but higher earnings than Nyxoah. NeuroOne Medical Technologies is trading at a lower price-to-earnings ratio than Nyxoah, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Nyxoah$11.33M5.47-$101.92M-$2.52N/A
NeuroOne Medical Technologies$9.47M1.70-$3.61M-$0.95N/A

Nyxoah has a beta of 1.62, indicating that its stock price is 62% more volatile than the broader market. Comparatively, NeuroOne Medical Technologies has a beta of 0.61, indicating that its stock price is 39% less volatile than the broader market.

16.1% of NeuroOne Medical Technologies shares are owned by institutional investors. 17.1% of Nyxoah shares are owned by insiders. Comparatively, 11.8% of NeuroOne Medical Technologies shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

NeuroOne Medical Technologies has a net margin of -71.50% compared to Nyxoah's net margin of -443.16%. NeuroOne Medical Technologies' return on equity of -128.12% beat Nyxoah's return on equity.

Company Net Margins Return on Equity Return on Assets
Nyxoah-443.16% -178.90% -81.83%
NeuroOne Medical Technologies -71.50%-128.12%-86.34%

Summary

NeuroOne Medical Technologies beats Nyxoah on 9 of the 16 factors compared between the two stocks.

How does NeuroOne Medical Technologies compare to Health Sciences Acquisitions Co. 2?

NeuroOne Medical Technologies (NASDAQ:NMTC) and Health Sciences Acquisitions Co. 2 (NASDAQ:HSAQ) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, institutional ownership, media sentiment, valuation and dividends.

NeuroOne Medical Technologies has a beta of 0.61, indicating that its share price is 39% less volatile than the broader market. Comparatively, Health Sciences Acquisitions Co. 2 has a beta of 0.09, indicating that its share price is 91% less volatile than the broader market.

Health Sciences Acquisitions Co. 2 has a net margin of 0.00% compared to NeuroOne Medical Technologies' net margin of -71.50%. Health Sciences Acquisitions Co. 2's return on equity of 0.00% beat NeuroOne Medical Technologies' return on equity.

Company Net Margins Return on Equity Return on Assets
NeuroOne Medical Technologies-71.50% -128.12% -86.34%
Health Sciences Acquisitions Co. 2 N/A N/A -2.38%

In the previous week, NeuroOne Medical Technologies had 5 more articles in the media than Health Sciences Acquisitions Co. 2. MarketBeat recorded 5 mentions for NeuroOne Medical Technologies and 0 mentions for Health Sciences Acquisitions Co. 2. NeuroOne Medical Technologies' average media sentiment score of 0.41 beat Health Sciences Acquisitions Co. 2's score of 0.00 indicating that NeuroOne Medical Technologies is being referred to more favorably in the media.

Company Overall Sentiment
NeuroOne Medical Technologies Neutral
Health Sciences Acquisitions Co. 2 Neutral

Health Sciences Acquisitions Co. 2 has lower revenue, but higher earnings than NeuroOne Medical Technologies.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NeuroOne Medical Technologies$9.47M1.70-$3.61M-$0.95N/A
Health Sciences Acquisitions Co. 2N/AN/A-$380KN/AN/A

16.1% of NeuroOne Medical Technologies shares are owned by institutional investors. Comparatively, 89.7% of Health Sciences Acquisitions Co. 2 shares are owned by institutional investors. 11.8% of NeuroOne Medical Technologies shares are owned by company insiders. Comparatively, 21.9% of Health Sciences Acquisitions Co. 2 shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

NeuroOne Medical Technologies currently has a consensus target price of $7.33, indicating a potential upside of 314.31%. Given NeuroOne Medical Technologies' stronger consensus rating and higher possible upside, research analysts clearly believe NeuroOne Medical Technologies is more favorable than Health Sciences Acquisitions Co. 2.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
NeuroOne Medical Technologies
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.40
Health Sciences Acquisitions Co. 2
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Summary

NeuroOne Medical Technologies beats Health Sciences Acquisitions Co. 2 on 7 of the 13 factors compared between the two stocks.

How does NeuroOne Medical Technologies compare to Daxor?

Daxor (NASDAQ:DXR) and NeuroOne Medical Technologies (NASDAQ:NMTC) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, analyst recommendations, media sentiment, institutional ownership and earnings.

Daxor has a beta of 0.27, indicating that its stock price is 73% less volatile than the broader market. Comparatively, NeuroOne Medical Technologies has a beta of 0.61, indicating that its stock price is 39% less volatile than the broader market.

1.3% of Daxor shares are owned by institutional investors. Comparatively, 16.1% of NeuroOne Medical Technologies shares are owned by institutional investors. 51.5% of Daxor shares are owned by insiders. Comparatively, 11.8% of NeuroOne Medical Technologies shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Daxor has higher earnings, but lower revenue than NeuroOne Medical Technologies.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
DaxorN/AN/AN/AN/AN/A
NeuroOne Medical Technologies$9.47M1.70-$3.61M-$0.95N/A

NeuroOne Medical Technologies has a consensus target price of $7.33, suggesting a potential upside of 314.31%. Given NeuroOne Medical Technologies' higher probable upside, analysts plainly believe NeuroOne Medical Technologies is more favorable than Daxor.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Daxor
0 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.50
NeuroOne Medical Technologies
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.40

Daxor has a net margin of 0.00% compared to NeuroOne Medical Technologies' net margin of -71.50%. Daxor's return on equity of 0.00% beat NeuroOne Medical Technologies' return on equity.

Company Net Margins Return on Equity Return on Assets
DaxorN/A N/A N/A
NeuroOne Medical Technologies -71.50%-128.12%-86.34%

In the previous week, NeuroOne Medical Technologies had 4 more articles in the media than Daxor. MarketBeat recorded 5 mentions for NeuroOne Medical Technologies and 1 mentions for Daxor. Daxor's average media sentiment score of 1.89 beat NeuroOne Medical Technologies' score of 0.41 indicating that Daxor is being referred to more favorably in the media.

Company Overall Sentiment
Daxor Very Positive
NeuroOne Medical Technologies Neutral

Summary

Daxor and NeuroOne Medical Technologies tied by winning 6 of the 12 factors compared between the two stocks.

Get NeuroOne Medical Technologies News Delivered to You Automatically

Sign up to receive the latest news and ratings for NMTC and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NMTC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

NMTC vs. The Competition

Export
MetricNeuroOne Medical TechnologiesHealthcare Equipment & Supplies IndustryHealthcare SectorNASDAQ Exchange
Market Cap$16.12M$5.84B$7.20B$12.90B
Dividend YieldN/A1.75%2.54%11.28%
P/E Ratio-1.8625.92273.1625.45
Price / Sales1.7068.06592.3271.88
Price / CashN/A33.0376.7453.00
Price / Book4.326.1812.986.14
Net Income-$3.61M$149.01M$3.48B$348.86M
7 Day Performance-12.81%-0.24%0.13%-0.80%
1 Month Performance4.12%6.18%7.08%4.13%
1 Year Performance-61.40%6.30%24.67%15.17%

NeuroOne Medical Technologies Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NMTC
NeuroOne Medical Technologies
2.468 of 5 stars		$1.77
-10.6%		$7.33
+314.3%		-61.4%$16.12M$9.47MN/A20
NRXS
NeurAxis
N/A$6.04
-0.5%		$13.00
+115.2%		+136.2%$75.85M$5.32MN/A19
NNOX
Nano-X Imaging
4.2584 of 5 stars		$0.86
-0.1%		$4.33
+402.1%		-78.6%$67.92M$13.02MN/A190
NYXH
Nyxoah
2.9508 of 5 stars		$1.64
+1.2%		$4.26
+159.9%		-74.4%$62.79M$11.33MN/A110
HSAQ
Health Sciences Acquisitions Co. 2
N/A$5.44
+1.5%		N/A+91.3%$60.99MN/AN/A4

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:NMTC) was last updated on 8/30/2026 by MarketBeat.com Staff.
From Our Partners
The retirement stock I'd buy before Nvidia today
In 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Ch...
Chaikin Analytics | Sponsoredtc pixel
Why major institutions are piling into this digital asset now
BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...
Awesomely | Sponsoredtc pixel
Bank of America: 'Digital Dollar Inevitable'
Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...
Decentralized Masters | Sponsoredtc pixel
A Worldwide Gold Lockdown Is Now Underway
Gold has spiked above $4,400 an ounce as central bankers stockpile at one of the fastest paces in decades, acc...
Stansberry Research | Sponsoredtc pixel
Buy These Stocks Before August 31st
Keith Kaplan has invested $17 million into his own AI research platform, now used by 180,000 investors worldwi...
TradeSmith | Sponsoredtc pixel
Bank of America grew this stake 139%
Bank of America raised its stake in a small gold company by 139%. Jane Street increased its position by 159%, ...
Behind the Markets | Sponsoredtc pixel
The trade I’ve been waiting for since 2011
Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...
Traders Agency | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel